(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...

Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...

Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...

In a breakthrough that could potentially rewrite the prevention and treatment of cancer, scientists have discovered how ...

Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the cells that produce insulin—a ...

Moderna (MRNA) announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with ...

Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

The super adjuvant vaccine also protected against the spread of cancer to the lungs. When exposed to melanoma cells systemically, which mimics how cancer metastasizes, none of the ...

Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025  Oxford, United Kingdom – October 3, 2025. Enara Bio, a ...

ATLANTA, GA - April 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today ...